

## AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

### Listing of Claims:

1. (Previously Presented) A method for alleviating a symptom of condition associated with prostate cancer selected from the group consisting of prostatic enlargement, urinary incontinence, urinary retention, and urge-type dysfunction, the method comprising the step of administering injecting a therapeutic amount of botulinum toxin type A into the prostate gland of a patient with prostate cancer, thereby alleviating a symptom of said condition associated with prostate cancer, wherein the symptom of prostate cancer is selected from the group consisting of prostatic enlargement, urinary incontinence, urinary retention, urge-type dysfunction, unstable bladder, unstable sphincter, and recurrent urinary infection.
2. (Cancelled)
3. (Cancelled)
4. (Currently Amended) The method of claim 1, wherein the symptom of condition associated with prostate cancer is urinary incontinence.
5. (Currently Amended) The method according to claim 1, where the patient is a human male.
- 6-19. (Cancelled)
20. (Currently Amended) The method of claim 1, wherein the symptom-condition is prostatic enlargement.
21. (Cancelled)
22. (New) The method of claim 1, wherein the therapeutically effective amount of botulinum toxin type A is up to 2500 units.
23. (New) The method of Claim 1, wherein the therapeutically effective amount of botulinum toxin type A is about 1.4 IU/kg to 17.1 IU/kg of botulinum toxin type A.
24. (New) The method of Claim 1, wherein the therapeutically effective amount of botulinum toxin type A is 200 IU of botulinum toxin type A.